Morgan Stanley Maintains Equal-Weight on Moderna, Lowers Price Target to $123
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Matthew Harrison has maintained an Equal-Weight rating on Moderna (NASDAQ:MRNA) and lowered the price target from $128 to $123.
August 04, 2023 | 6:19 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Morgan Stanley has maintained an Equal-Weight rating on Moderna and lowered the price target from $128 to $123.
The lowering of the price target by Morgan Stanley could potentially lead to a decrease in Moderna's stock price in the short term. Investors may interpret this as a sign of decreased future performance, which could lead to selling pressure.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100